USSTOCK.TODAY
Market Closed
Log in Sign up

Aptevo Therapeutics Announces Substantial Reduction in Mipretamig-Related Infusion Reactions

ACCESSWIRE +1 · ·by G4L

APVO
APVO Aptevo Therapeutics Inc
$1.13 -8.87%
View chart & analysis →
  1. 1Aptevo Therapeutics has achieved a clinical development milestone that substantially reduces infusion-related reactions (IRR) for mipretamig.
  2. 2Aptevo Therapeutics plans to complete the RAINIER dose optimization study by the end of 2026.
  3. 3Aptevo Therapeutics is expected to begin Phase 2 clinical development in 2027.

So what's the key point?

Aptevo Therapeutics has succeeded in significantly reducing side effects that occur when using its medication. Based on this achievement, the company plans to start the next stage of clinical trials in 2027.

Source ACCESSWIRE +1 · View original ↗

Related 3-line summaries

Aptevo Therapeutics Inc. Announces Preclinical Data Showing Potential to Overcome Immune Suppression in Solid Tumors ACCESSWIRE +1 · 33m agoAptevo Reports 93% Clinical Benefit Rate with Mipleta... Triple Combo in TP53-Mutant AML ACCESSWIRE +1 · Sep 3Sphere 3D Releases Q2 Results and Business Update Following Cathedra Merger Newsfile +1 · Aug 14
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news